---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017655"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T20:28:13.435031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q3 net loss $29.3M, revenue $9.3M; zunsemetinib RA data due Nov 2023

## Summary
- Net loss of $29.3M for Q3 2023 compared to $20.0M in Q3 2022.
- Total revenue $9.3M, down from $19.0M due to prior year Lilly payment.
- Cash and securities $187.0M as of Sept 30, 2023; sufficient through end of 2025.
- Zunsemetinib Phase 2b RA topline data expected November 2023.
- ATI-1777 Phase 2b AD data expected around year-end 2023.

## SEC filing metadata
- accession: 0001558370-23-017655
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/0001558370-23-017655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/acrs-20231106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017655
- JSON: https://secwatch.observer/filing/0001558370-23-017655.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017655.txt

## Key facts
- Earnings Releases
  Aclaris Therapeutics, Inc. reported third quarter of 2023 results: revenue $9.3 million, net income net loss was $29.3 million.
  - Period: third quarter of 2023
  - Revenue: $9.3 million
  - Net income: net loss was $29.3 million
  - Result: reported results
  source text: Results ​ Third Quarter 2023 ​ ● Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022. ​ ● Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022. The decrease was primarily driven by a one-time upfront payment under the non- ​ ​
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/0001558370-23-017655-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.